Estatísticas Básicas
| CIK | 1820190 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vickers Vantage Corp I
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| June 2, 2026 |
As filed with the U.S. Securities and Exchange Commission on June 2, 2026 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdiction of incorpo |
|
| June 2, 2026 |
Calculation of Filing Fee Tables S-3 Scilex Holding Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, $0. |
|
| May 20, 2026 |
THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company |
|
| May 20, 2026 |
COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of January 29, 2026, by and between Quantum Scan Holdings, Inc. |
|
| May 20, 2026 |
Execution Version STOCK ACQUISITION AGREEMENT by and among PHOENIX ASIA HOLDINGS LIMITED, AS TRANSFEREE, ACEA PHARMA, INC. |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-39852 CUSIP Number: 80880W106 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran |
|
| May 11, 2026 |
Dear Scilex Holding Company Stockholders and other holders of Scilex Holding Company Securities: Exhibit 99.1 Dear Scilex Holding Company Stockholders and other holders of Scilex Holding Company Securities: This letter is being furnished to you as a holder of certain securities of Scilex Holding Company, a Delaware corporation (the “Company”). As the Company previously announced, its board of directors (the “Board”) declared a dividend (the “Dividend”) of Dream Bowl Meme Coin I tokens held by |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) 9 |
|
| May 11, 2026 |
Scilex Holding Company FREQUENTLY ASKED QUESTIONS REGARDING THE Dream Bowl Meme Coin I DIVIDEND Exhibit 99.4 Scilex Holding Company FREQUENTLY ASKED QUESTIONS REGARDING THE Dream Bowl Meme Coin I DIVIDEND This FAQ addresses details of the distribution of the Dream Bowl Meme Coin I tokens to certain record holders of common stock and certain other equity securities of Scilex Holding Company (the “Company”), including the record date, payment date, distribution ratio, opt-in and digital wallet |
|
| May 11, 2026 |
Form of Scilex Holding Company Opt-In Agreement Exhibit 99.2 Form of Scilex Holding Company Opt-In Agreement The undersigned (“me” or “I”) understands that Scilex Holding Company, a Delaware corporation (the “Company”), declared a dividend (the “Dividend”) of Dream Bowl Meme Coin I tokens (such tokens, the “Dream Bowl Tokens”) to the holders of the following Company securities, in each case as of the close of business on April 30, 2026 (such da |
|
| May 11, 2026 |
Onboarding Documentation - Datavault AI Wallet Creation Exhibit 99.3 Onboarding Documentation - Datavault AI Wallet Creation Step 1: Visit https://datavault.one/ Step 2: Click Create an Account! Step 3: Enter personal email address to create Datavault username. Step 4: Open personal email to retrieve activation code Step 5: Copy and paste Activation Code or click Activate Account link. Create Password based on password requirements listed. Step 6: Logi |
|
| May 5, 2026 |
FOR IMMEDIATE RELEASE May 6, 2026 Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) 92 |
|
| May 5, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exac |
|
| April 30, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| April 16, 2026 |
As filed with the U.S. Securities and Exchange Commission on April 16, 2026 S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdiction of incorp |
|
| April 16, 2026 |
Calculation of Filing Fee Tables S-3 Scilex Holding Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Common Stock, $0. |
|
| April 16, 2026 |
Scilex Holding Company Dated as of [ ] EX-4.21 Exhibit 4.21 Scilex Holding Company INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establi |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exac |
|
| April 10, 2026 |
Subsidiaries of Scilex Holding Company Exhibit 21.1 Subsidiaries of Scilex Holding Company Name State or Jurisdiction of Incorporation or Organization Scilex, Inc. Delaware Scilex Pharmaceuticals Inc. Delaware Semnur Pharmaceuticals, Inc. Delaware Semnur, Inc. Delaware Semnur (BVI), Limited British Virgin Islands Scilex (BVI), Limited British Virgin Islands SCLX Stock Acquisition JV LLC Texas SCLX DRE Holdings LLC Delaware Scilex Bio, |
|
| April 10, 2026 |
DESCRIPTION OF SECURITIES OF SCILEX HOLDING COMPANY Exhibit 4.16 DESCRIPTION OF SECURITIES OF SCILEX HOLDING COMPANY General The following description summarizes the most important terms of the securities of Scilex Holding Company (the “Company”, “we”, “us” or “our”). The following summary does not purport to be complete and is subject to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), the Compa |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-39852 CUSIP Number: 80880W106 (Check One): ☒Form 10-K ☐ Form 20-F ☐ Form 11-K ☐Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| March 13, 2026 |
Exhibit 99.1 FOR IMMEDIATE RELEASE March 13, 2026 Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties PALO ALTO, CALIFORNIA – Marc |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| March 13, 2026 |
Exhibit 99.1 KASOWITZ LLP Daniel A. Saunders (SBN 161051) [email protected] Robert W. Bosslet (SBN 278027) [email protected] 1801 Century Park East, Suite 1830 Los Angeles, California 90067 Telephone: (424) 288-7900 Facsimile: (424) 288-7901 Marc E. Kasowitz (pro hac vice application forthcoming) [email protected] Ronald R. Rossi (pro hac vice application forthcoming) RRossi@kasowitz |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| February 23, 2026 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| February 23, 2026 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| February 23, 2026 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 18 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| February 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numb |
|
| February 20, 2026 |
Exhibit 10.1 WARRANT AGREEMENT This Warrant Agreement (this “Agreement”) is dated as of February 19, 2026 (the “Effective Date”), between Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”) and Oramed Pharmaceuticals Inc. (the “Holder”). Capitalized terms not defined herein shall have the meaning as set forth in the Warra |
|
| February 20, 2026 |
Exhibit 4.1 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATI |
|
| February 13, 2026 |
DRS Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY SCILEX HOLDING COMPANY PURSUANT TO 17 C. |
|
| February 13, 2026 |
Scilex Holding Company Dated as of [ ] EX-4.22 Exhibit 4.22 Scilex Holding Company INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establi |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 6, 2026 S-8 As filed with the Securities and Exchange Commission on February 6, 2026 Registration No. |
|
| February 9, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Scilex Holding Co Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0. |
|
| February 3, 2026 |
EX-3.1 Exhibit 3.1 SCILEX HOLDING COMPANY CERTIFICATE OF ELIMINATION OF SERIES 1 MANDATORY EXCHANGEABLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware In accordance with Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), Scilex Holding Company, a corporation organized and existing under the General Corporation Law o |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission |
|
| February 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2026 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| January 6, 2026 |
Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 RW Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 VIA EDGAR January 6, 2026 U. |
|
| December 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numb |
|
| December 29, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-292157 PROSPECTUS SCILEX HOLDING COMPANY Up to 500,000 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 1,703,946 Shares of Common Stock This prospectus relates to the issuance by us of up to an aggregate of 500,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), issuable upon |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numb |
|
| December 17, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 17, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numb |
|
| December 17, 2025 |
Exhibit 10.1 NON-RECOURSE LOAN AND SECURITIES PLEDGE AGREEMENT BETWEEN THE ST. JAMES BANK & TRUST COMPANY LTD. AND SCLX STOCK ACQUISITION JV LLC TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 4 ARTICLE II LOAN AND PLEDGED SECURITIES 5 2.1 Loan Terms 5 2.2 Pledged Securities; Tranches 6 2.3 Dealing with the Pledged Securities 7 ARTICLE III MATURITY DATE, PREPAYMENT, |
|
| December 17, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 17 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 16, 2025 |
Calculation of Filing Fee Tables S-1 Scilex Holding Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| December 16, 2025 |
EX-21.1 Exhibit 21.1 Subsidiaries of Scilex Holding Company Name State or Jurisdiction of Incorporation or Organization Scilex, Inc. Delaware Scilex Pharmaceuticals Inc Delaware Semnur Pharmaceuticals, Inc. Delaware SCLX Stock Acquisition JV LLC Texas SCLX DRE Holdings LLC Delaware Scilex Bio, Inc. Delaware |
|
| December 16, 2025 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdiction of incorp |
|
| December 12, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| December 12, 2025 |
THE ST. JAMES BANK & TRUST COMPANY LTD. SCILEX HOLDING COMPANY Exhibit 10.1 AMENDMENT TO NON-RECOURSE LOAN AND SECURITIES PLEDGE AGREEMENT This Amendment to Non-Recourse Loan and Securities Pledge Agreement (this “Amendment”) is made and effective as of December 8, 2025 between The St. James Bank and Trust Company Ltd. and Scilex Holding Company. WHEREAS: A. the parties hereto are parties to a Non-Recourse Loan and Securities Pledge Agreement dated as of Dece |
|
| December 12, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 12, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 16 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 11, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numb |
|
| December 11, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 11, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| December 5, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 5, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 5, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| December 5, 2025 |
THE ST. JAMES BANK & TRUST COMPANY LTD. SCILEX HOLDING COMPANY Exhibit 10.1 NON-RECOURSE LOAN AND SECURITIES PLEDGE AGREEMENT BETWEEN THE ST. JAMES BANK & TRUST COMPANY LTD. AND SCILEX HOLDING COMPANY TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 4 ARTICLE II LOAN AND PLEDGED SECURITIES 5 2.1 Loan Terms 5 2.2 Pledged Securities; Tranches 6 2.3 Dealing with the Pledged Securities 7 ARTICLE III MATURITY DATE, PREPAYMENT, REPAYME |
|
| December 1, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| December 1, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| December 1, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 25, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| December 1, 2025 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE November 26, 2025 Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc. • Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) co |
|
| November 24, 2025 |
EX-10.1 Exhibit 10.1 SCILEX HOLDING COMPANY November 23, 2025 Holder of Warrants Issued in April 2024 and December 2024 Re: Inducement Offer to Exercise Warrants Issued in April 2024 and December 2024 Dear Holder: Scilex Holding Company (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the Company’s |
|
| November 24, 2025 |
EX-10.2 Exhibit 10.2 [FORM OF WARRANT] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU |
|
| November 24, 2025 |
[FORM OF PLACEMENT AGENT WARRANT] EX-10.3 Exhibit 10.3 [FORM OF PLACEMENT AGENT WARRANT] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR S |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| November 24, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| November 24, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| November 24, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of |
|
| November 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Comp |
|
| November 7, 2025 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 4, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| November 4, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE November 4, 2025 Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from DataVault AI PALO ALTO, CALIFORNIA – November 4, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX |
|
| November 4, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Commo |
|
| November 4, 2025 |
EXCLUSIVE LICENSE AGREEMENT This License Agreement (this “Agreement”) is made as of the 3rd day of November 2025 (the “Effective Date”), by and between Datavault AI Inc. |
|
| October 31, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 31, 2025 |
TERMINATION AGREEMENT This Termination Agreement (this “Agreement”) is entered into as of October 30, 2025, by and between Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”), and Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, California 94303 (the “Company” and, together with the Investor, the “Parties”). |
|
| October 31, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 31, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| October 28, 2025 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 7, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 7, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number |
|
| October 7, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 2, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 2, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 2, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Num |
|
| October 1, 2025 |
Exhibit 10.1 WARRANT EXERCISE AGREEMENT This Warrant Exercise Agreement (this “Agreement”) is dated as of September 30, 2025 (the “Effective Date”), among Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”) and the undersigned investor (the “Holder”). Capitalized terms not defined herein shall have the meaning as set fort |
|
| October 1, 2025 |
Exhibit 10.2 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT |
|
| September 29, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| September 29, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| September 29, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Num |
|
| September 26, 2025 |
Exhibit 99.2 FOR IMMEDIATE RELEASE September 26, 2025 Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI PALO ALTO, CALIFORNIA – September 26, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain |
|
| September 26, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2025, between Datavault AI Inc., a Delaware corporation (the “Company”), and Scilex Holding Company, a Delaware corporation (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an e |
|
| September 26, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE September 23, 2025 Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin PALO ALTO, CALIFORNIA – September 23, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (“Scilex” or the “Comp |
|
| September 26, 2025 |
EX-10.1 ***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. *** Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), is dated as of September 22, 2025, by and be |
|
| September 26, 2025 |
Exhibit 99.2 Capitalized terms used but not otherwise defined in this Exhibit 99.2, shall have their respective meanings as set forth in the Form 8-K to which this Exhibit is attached. Risks Related to Cryptocurrency The Company intends to use the net proceeds from the Biconomy Resale SPA to purchase or otherwise acquire Bitcoin and to fund investments in other companies. The price of Bitcoin has |
|
| September 26, 2025 |
Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI Exhibit 99.1 FOR IMMEDIATE RELEASE September 25, 2025 Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI PALO ALTO, CALIFORNIA – September 26, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management produ |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissi |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 25, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Num |
|
| September 26, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 23, 2025, by and among Scilex Holding Company, a Delaware corporation, with headquarters located at 960 San Antonio Road, Palo Alto, CA 94303 (“SHC”), Scilex, Inc., a Delaware corporation and wholly owned subsidiary of SHC (“Scilex, Inc.” and together with SHC, each a “Seller” and joi |
|
| August 21, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission |
|
| August 21, 2025 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 21, 2025 Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur |
|
| August 21, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| August 21, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Co |
|
| August 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| August 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| August 14, 2025 |
Filed Pursuant to Rule 424(b)(3) PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated May 13, 2025) Registration No. 333-275117 SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common S |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company ( |
|
| August 4, 2025 |
List of Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 Subsidiaries of Scilex Holding Company Name State or Jurisdiction of Incorporation or Organization Scilex, Inc. Delaware Scilex Pharmaceuticals Inc Delaware Semnur Pharmaceuticals, Inc. Delaware SCLX Stock Acquisition JV LLC Texas SCLX DRE Holdings LLC Delaware Scilex Bio, Inc. Delaware |
|
| August 4, 2025 |
Calculation of Filing Fee Tables S-1 Scilex Holding Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| August 4, 2025 |
Power of Attorney (included on the signature page hereto). Table of Contents As filed with the U.S. Securities and Exchange Commission on August 4, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdiction of incorpora |
|
| July 23, 2025 |
EX-10.4 Exhibit 10.4 WARRANT EXCHANGE AGREEMENT This WARRANT EXCHANGE AGREEMENT (the “Agreement”), dated as of July 22, 2025, is by and between Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”) and the undersigned (the “Holder”). Capitalized terms used but not defined herein are used with the respective meanings assigne |
|
| July 23, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 1,402,955 Warrants This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 23, 2025 |
EX-10.7 Exhibit 10.7 Execution Version July 22, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Option Agreement for the Repurchase of Warrants (this “Agreement”) Ladies and Gentlemen: Reference is made to (i) the following warrants, each dated September 21, 2023, issued by Scilex Holding Company, a Delaware corporation (“Scilex” or “Purchaser”), |
|
| July 23, 2025 |
EX-10.5 Exhibit 10.5 WARRANT EXCHANGE AGREEMENT This WARRANT EXCHANGE AGREEMENT (the “Agreement”), dated as of July 22, 2025, is by and between Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”) and the undersigned (the “Holder”). Capitalized terms used but not defined herein are used with the respective meanings assigne |
|
| July 23, 2025 |
Exhibit 10.3 WARRANT EXCHANGE AGREEMENT This WARRANT EXCHANGE AGREEMENT (the “Agreement”), dated as of July 22, 2025, is by and between Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”) and the undersigned (the “Holder”). Capitalized terms used but not defined herein are used with the respective meanings assigned to the |
|
| July 23, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 3,593,288 Shares of Common Stock Up to 3,250,000 Shares of Common Stock offered by the Selling Securityholder This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration state |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 23, 2025 |
EX-10.1 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT dated as of July 22, 2025 by and between SCILEX HOLDING COMPANY and TUMIM STONE CAPITAL, LLC TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE OF COMMON STOCK 1 Section 2.1 Purchase and Sale of Stock 1 Section 2.2 Closing Date; Settlement Dates 2 Section 2.3 Initial Public Announcement and Required Filings 2 Section 2.4 Comm |
|
| July 23, 2025 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 22, 2025, is by and between Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”), and Scilex Holding Company, a Delaware corporation (the “Company”). RECITALS WHEREAS, the Company and the Investor have entered into that certain Common Stock Purchase |
|
| July 23, 2025 |
EX-10.6 Exhibit 10.6 [FORM OF WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. SCILEX HOLDING COMPANY WARRANT TO PURCHASE COMMON STOCK Warrant No.: Date of Issuance: October 8, 2024 (“Issuance Date”) Date of Exchange: 2025 (“Exchange Date”) Scilex Holding Company, |
|
| July 23, 2025 |
SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| July 23, 2025 |
EX-2.1 Exhibit 2.1 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of July 22, 2025, is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub Inc., a De |
|
| June 24, 2025 |
SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock ________________ Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No. 2 wa |
|
| June 24, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 3,593,288 Shares of Common Stock Up to 3,250,000 Shares of Common Stock offered by the Selling Securityholder This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration state |
|
| June 24, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 1,402,955 Warrants This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part o |
|
| June 23, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| June 23, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE June 23, 2025 Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board PALO ALTO, CALIFORNIA – June 23, 2025 (GLOBE NEWSWIRE) |
|
| June 23, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) 9 |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Na |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 15, 2025 |
SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock ________________ Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No. 2 wa |
|
| May 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280882 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 3,593,288 Shares of Common Stock Up to 3,250,000 Shares of Common Stock offered by the Selling Securityholder This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration state |
|
| May 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated May 13, 2025) SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 1,402,955 Warrants This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part o |
|
| May 14, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280882 PROSPECTUS SCILEX HOLDING COMPANY Up to 3,593,288 Shares of Common Stock Up to 3,250,000 Shares of Common Stock offered by the Selling Securityholder This prospectus relates to the issuance by us of up to an aggregate of 3,593,288 shares of our Common Stock issuable as follows: (i) 122,132 shares of Common Stock i |
|
| May 14, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SCILEX HOLDING COMPANY Up to 1,594,207 Shares of Common Stock Up to 198,810 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 1,402,955 Warrants This prospectus relates to the issuance by us of up to an aggregate of 198,810 shares of our common stock, par value $0.0001 per share (“Comm |
|
| May 14, 2025 |
SCILEX HOLDING Up to 6,685,714 Shares of Common 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SCILEX HOLDING COMPANY Up to 6,685,714 Shares of Common Stock This prospectus relates to the resale from time to time by the selling stockholder named in this prospectus (including its permitted transferees, donees, pledgees and other successors-in-interest) (the “Selling Stockholder”) of up to an aggre |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company |
|
| May 12, 2025 |
Scilex Holding Company Amended and Restated Non-Employe Director Compensation Policy. Exhibit 10.1 SCILEX HOLDING COMPANY (THE “COMPANY”) AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (THE “POLICY”) Annual Cash Compensation Amount Board Members $82,500 Chairs of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercialization and Transaction Committee $37,500 Other Members of the Audit Committee, Compensation Committe |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) 92 |
|
| May 7, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 7, 2025 Registration No. 333-275117 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdict |
|
| May 7, 2025 |
Exhibit 10.76 April 16, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note and Related Transaction Documents (this “Consent, Waiver and Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of October 7, 2024 (the “SPA” |
|
| May 7, 2025 |
Exhibit 10.77 April 16, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note and Related Transaction Documents (this “Consent, Waiver and Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of October 7, 2024 (the “SPA” |
|
| May 7, 2025 |
Exhibit 10.75 April 16, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note and Related Transaction Documents (this “Consent, Waiver and Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of September 21, 2023 (the “SP |
|
| May 7, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 7, 2025 Registration No. 333-268603 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 3 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdict |
|
| May 7, 2025 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on May 7, 2025 Registration Nos. 333-280882 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) Delaware 2836 92-10 |
|
| May 7, 2025 |
Exhibit 10.78 April 16, 2025 Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note and Related Transaction Documents (this “Consent, Waiver and Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of October 7, 2024 (the “SPA” |
|
| May 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Scilex Holding Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities N/A Table 2: Fee Offset Claims and Sources N/A Table 3: Combined Prospectuses Security Type Security Class Title Amount of Securities Previously Registered(1)(2) Maximum Aggregate Offering Price of Securities Previously Registered(2) Form Type File Number Initial Effective Date Equity Common Stock, par value $0. |
|
| April 30, 2025 |
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule Exhibit 99.1 FOR IMMEDIATE RELEASE April 30, 2025 Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule PALO ALTO, CALIFORNIA – April 30, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of ac |
|
| April 30, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39852 Scilex |
|
| April 22, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE April 22, 2025 Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 PALO ALTO, CALIFORNIA – April 22, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (Na |
|
| April 22, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| April 21, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| April 21, 2025 |
Execution Version Exhibit 2.1 AMENDMENT NO.1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of April 16, 2025, is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission F |
|
| April 15, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SCILEX HOLDING COMPANY Scilex Holding Company, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that: A. The name of the Corporation is Scilex Holding Company. The Corporation was originally incorporated under the name “Vickers Vantage Corp. I”, |
|
| April 11, 2025 |
Scilex Holding Company Announces 1-for-35 Reverse Stock Split EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE April 11, 2025 Scilex Holding Company Announces 1-for-35 Reverse Stock Split PALO ALTO, CALIFORNIA – April 11, 2025 (GLOBE NEWSWIRE) – Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 S-8 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Scilex Holding Company (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, par value $0. |
|
| March 31, 2025 |
Exhibit 10.33 *** Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. *** SECOND AMENDMENT TO MASTER SERVICES AGREEMENT THIS SECOND AMENDMENT (“Amendment No. 2”) to the Master Services Agreem |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exac |
|
| March 31, 2025 |
Description of Securities of Scilex Holding Company. Exhibit 4.16 DESCRIPTION OF SECURITIES OF SCILEX HOLDING COMPANY General The following description summarizes the most important terms of the securities of Scilex Holding Company (the “Company”, “we”, “us” or “our”). The following summary does not purport to be complete and is subject to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), the Compa |
|
| March 31, 2025 |
Exhibit 10.37 *** Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. *** Execution Version FIRST AMENDMENT TO LICENSE AND COMMERCIALIZATION AGREEMENT This FIRST AMENDMENT TO LICENSE AND COMM |
|
| March 20, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 27 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| March 20, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 26 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| March 20, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| March 10, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE March 10, 2025 Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 PALO ALTO, CALIFORNIA – March 10, 2025 (GLOBE NEWSWIRE) - Scilex Holding Compan |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Number) |
|
| March 5, 2025 |
Up to $170,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276245 PROSPECTUS SUPPLEMENT DATED MARCH 5, 2025 (To Prospectus dated January 11, 2024) Up to $170,000,000 Common Stock This Prospectus Supplement, or this Supplement, amends and supplements the information in the sales agreement prospectus, dated January 11, 2024, or the Sales Agreement Prospectus, contained in the Registration Statement on Fo |
|
| March 3, 2025 |
Exhibit 10.3 Execution Version SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of February 28, 2025, by and between EFSHAR HATAYA LTD, a Marshall Islands corporation, in its capacity as agent for itself and the other Royalty Secured Parties (as defined below) (together with its successors and assigns, “Royalty Agent”), and SCILEX HOLDING COMPANY, a Delawa |
|
| March 3, 2025 |
Exhibit 10.5 Execution Version GLOPERBA LICENSE AGREEMENT dated as of February 28, 2025 by and between SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Licensor Parties and ROYALTYVEST LTD. as Licensee ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 8 ARTICLE II REPRESENTATIONS AND WARRANTIES 10 Section 2.1 Mutual Represe |
|
| March 3, 2025 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and entered into as of February 28, 2025 by and among Scilex Holding Company, a Delaware corporation (“Scilex”) and Scilex Pharmaceuticals Inc. (collectively with Scilex, “Grantor”), Efshar Hataya Ltd, a Marshall Islands corporation (“Murchinson”), in its capacity as agent (“Agent”) for Murchinson, |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 26 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| March 3, 2025 |
Exhibit 10.1 Execution Version PURCHASE AND SALE AGREEMENT dated as of February 28, 2025 by and among SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Seller Parties and EFSHAR HATAYA LTD, ORAMED PHARMACEUTICALS INC., and 3I, LP as the Purchasers ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 11 ARTICLE II PURCHASE AND S |
|
| March 3, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 25 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| March 3, 2025 |
Exhibit 10.4 Final Form AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT, dated as of February 28, 2025 (this “Amendment”), amends that certain PURCHASE AND SALE AGREEMENT (the “Purchase and Sale Agreement”), dated as of October 8, 2024, by and among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Seller”), SCILEX HOLDING COMPANY, a Delaw |
|
| February 27, 2025 |
Exhibit 10.2 February 22, 2025 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL Re: Parent Guarantee for Lidocaine License Agreement (this “Side Letter”) Ladies and Gentlemen: Reference is made to that Lidocaine License Agreement, dated as of February 22, 2025 (the “License Agreement”), between Scilex Pharmaceuticals, Inc. (“Licensor”) and RoyaltyVest Ltd. |
|
| February 27, 2025 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2025 |
Exhibit 10.1 LIDOCAINE LICENSE AGREEMENT dated as of February 22, 2025 by and between SCILEX PHARMACEUTICALS INC. as Licensor and ROYALTYVEST LTD. as Licensee ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 9 ARTICLE II REPRESENTATIONS AND WARRANTIES 10 Section 2.1 Mutual Representation and Warranties 10 Section 2.2 Licensor Represe |
|
| February 27, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 25 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| February 27, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 24 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| February 26, 2025 |
PRER14A Table of Contents PRELIMINARY COPY DATED FEBRUARY 26, 2025 — SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2025 |
Table of Contents PRELIMINARY COPY DATED FEBRUARY 14, 2025 — SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 23, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-1 begin 644 ck0001669811-ex1.pdf M)5!$1BTQ+C8-)>+CS],-"C0T,B P(&]B:@T\/"],:6YE87)I>F5D(#$O3" R M.3(V.#DO3R T-#0O12 U,3%LT-#(@ M.3==+TEN9F\@-#0Q(# @4B],96YG=&@@,C4R+U!R978@,CDQ-38R+U)O;W0@ M-#0S(# @4B]3:7IE(#4S.2]4>7!E+UA2968O5ULQ(#(@,5T^/G-TUY^OW/.\Z08ZD,*I?M,',J$\TRY Q,8 MP2LN[!N5/K&+[TP:MK E3:$1=>;FI&>=9Z1EM. 'W;:T29VX-'R2#O"!,E:* MN6J7([A!VL A^M3.2DO2O".;#7N*,J?%6^D*FWC!M(K)XJG'AC<6SE!]PJ/: M4VF: |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 21, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission |
|
| January 22, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 23 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendm |
|
| January 22, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 24 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| January 22, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE January 21, 2025 Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 PALO ALTO, CALIFORNIA – January 21, 2025 (GLOBE NEWSWIRE)—Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing |
|
| January 22, 2025 |
Exhibit 10.1 January 21, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu And Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Amendment to Senior Secured Promissory Note (this “Amendment”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchase Agreement, dated as of September 21, 2023 (the “S |
|
| January 21, 2025 |
Exhibit 99.2 FOR IMMEDIATE RELEASE January 21, 2025 Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) PALO ALTO, CALIFORNIA – January 21, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products |
|
| January 21, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE January 21, 2025 Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 PALO ALTO, CALIFORNIA – January 21, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pai |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 21, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39852 (Commission File Numbe |
|
| January 21, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 23 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| January 21, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 22 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Comp |
|
| January 17, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 22 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| January 17, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 21 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| January 6, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-10.1 begin 644 ck0001820190-ex101.pdf M)5!$1BTQ+C8-)>+CS],-"CF5D(#$O3" T M-S@R,C$O3R W-#4O12 V,S,T-R].(#$P+U0@-#%LW-#,@ M,3$X72]);F9O(#;-&*T9A&,;Q<86)0)45(,!I&D2*0P*(ID4+*( M8O '($E8Q. /L#&\1#(8E,+YO,5D^7;=UW4S[G/80X*HI"E&E.$76EB,^4 MV["7HF",>H6:%,DMKT69A:L4H1O6(:>EP2U/5!DO7QXKZY2G\*RL!M\-(U * MA;PI)QZ4"U %7X):Z@":X)QWK]FDX1TRO,5?+QGG?8 /):N"?:J-T'-4]." M2JH5'(NOP2S)!;4F>%1:21BRB![E(5A$U4!V^#&O1&Y8+\(H |
|
| January 6, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-10.5 begin 644 ck0001820190-ex105.pdf M)5!$1BTQ+C8-)>+CS],-"C(S,SD@,"!O8FH-/#PO3&EN96%R:7IE9" Q+TP@ M,3,W,C8W."]/(#(S-#$O12 V-38P-R].(#,V+U0@,3,V.#8S-B]((%L@-S(Y M(#0U.5T^/@UE;F1O8FH-(" @(" @(" @#0HR-#4P(# @;V)J#3P\+T1E8V]D M95!A;-&]*T91' ?P>^S/(.2#-Y+,C#((O\ B\5*>5F0#"))*9'" M0!2)4C)XB\7D69 H+%[^!)D,E,5@>#(\[N MC FZ8\('Y75,9A"[RC%I'T?*.O0A$Y/JBHDV$. 6 \BB1\L0*I0':,&2L59' M'BH+E22"BZ1,[8F'>M[ED[0B7,\8= |
|
| January 6, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-10.2 begin 644 ck0001820190-ex102.pdf M)5!$1BTQ+C8-)>+CS],-"C@S." P(&]B:@T\/"],:6YE87)I>F5D(#$O3" U M,C%LX,S@@ M,3$X72]);F9O(#@S-R P(%(O3&5N9W1H(#,P,"]0;-**T5A& ?P<]Y[+4HIOTLR,%C]!0P6,B'*PF 024J)%'=0U)4,2A81 M!G\ DH1%S"9E8$ [email protected]/ET&^*H/ I1MCTAZDN(SY7; MV$LHF4C(/$A=THDTH/NI/$)0EC''9[1@E=4IZ79T&3B3'I#F[(!X\HJE&$& M3\BA'C\X=+A1:L4%'K&/#V0=6?(QGF6FGXH?&$5!^C4G986I5D3=RFM:;PH)Z51BRANH[B(:YPZ=Z^["V-A. |
|
| January 6, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-10.4 begin 644 ck0001820190-ex104.pdf M)5!$1BTQ+C8-)>+CS],-"C,X,R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" R M-3$S-C0O3R S.#4O12 U-#DY-2].(#%LS.#,@ M,3 R72]);F9O(#,X,B P(%(O3&5N9W1H(#(V-2]0;-"*X51& ?P<\Y[643*%4HRL!@-)H/%8B9L# 8QR"06#$21;&(09;%9 MD$&QB#]!)@-%,AB4'@M^Z=+)^^SWF>\^-]4PSU(87L-2<.X5+9FU-5G5,8 M1H]R0"KJ[DG3N,E)1M*VOYQC$&<&;F3UBHC%BT;5/:\YJ5E!VPH/Y1M4@&U:,0< MBN64[4JVI4Z4/O\1LV@UXBNC,IMQ^8A&-UZPCW[\&#F |
|
| January 6, 2025 |
SCLX / Scilex Holding Company / SCLX Stock Acquisition JV LLC - EX-10.3 begin 644 ck0001820190-ex103.pdf M)5!$1BTQ+C8-)>+CS],-"CF5D(#$O3" T M-S@X-3DO3R W-#4O12 V,S,S."].(#$P+U0@-#%LW-#,@ M,3$X72]);F9O(#;-&[*X=A&,;Q]WU>!H-2SB49&*S^ @:+,B%BH5 B29%(.92B2 8EBR@& MFP5)PN*P6VP,"&4P*(7W\RLFR[?KNN[[.=U/B*.\*$19=2FBEA3Q";L!L] - M-Y#INX1V>(6]%*$U1;(":S9XH*H5GJ (,O80*N$8GO750CD[ (60*QNC[NTW M0Y7!%^RJ5E U<,K>Z=MFWR%+-D=ELF%P4/A06-*\0S7(1JAI:ERAE*VG,LM< M([J2G;'+\ A#T)<8-"F5N9'-T8 |
|
| January 3, 2025 |
EX-10.3 Exhibit 10.3 Execution Version January 2, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Deferral and Consent under Tranche B Senior Secured Convertible Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchas |
|
| January 3, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 21 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| January 3, 2025 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 20 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2025 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commission |
|
| January 3, 2025 |
EX-10.1 Exhibit 10.1 Execution Version January 2, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Deferral and Consent under Tranche B Senior Secured Convertible Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchas |
|
| January 3, 2025 |
EX-10.2 Exhibit 10.2 Execution Version January 2, 2025 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Deferral and Consent under Tranche B Senior Secured Convertible Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities Purchas |
|
| December 30, 2024 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE December 30, 2024 Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025 • Scilex notified NASDAQ on December 30, 2024 that it has set a ne |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2024 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| December 13, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 11, 2024, between Scilex Holding Company, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| December 13, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276245 PROSPECTUS SUPPLEMENT (To Prospectus dated January 11, 2024) Scilex Holding Company 26,355,347 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,401,132 Shares of Common Stock Up to 2,401,132 Shares of Common Stock Underlying the Pre-Funded Warrants Common Warrants to Purchase up to 57,512,958 Shares |
|
| December 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268603 PROSPECTUS SUPPLEMENT NO. 20 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 71,459,469 Shares of Common Stock Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants Up to 5,490,617 Warrants This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms |
|
| December 13, 2024 |
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering Exhibit 99.2 Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering PALO ALTO, Calif., December 13, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatment for neurodegenerative and cardiometabolic disease, and non-opioid pain man |
|
| December 13, 2024 |
Scilex Holding Company Announces $17 Million Registered Direct Offering Exhibit 99.1 Scilex Holding Company Announces $17 Million Registered Direct Offering PALO ALTO, Calif., December 12, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatment for neurodegenerative and cardiometabolic disease, and non-opioid pain management pro |
|
| December 13, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANY Warrant Shares: Issue Date: December 13, 2024 Initial Exercise Date: December 13, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| December 13, 2024 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANY Warrant Shares: Issue Date: December 13, 2024 Initial Exercise Date: June 13, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2024 SCILEX HOLDING COMPANY (Exact name of registrant as specified in its charter) Delaware 001-39852 92-1062542 (State or other jurisdiction of incorporation) (Commissio |
|
| December 13, 2024 |
Scilex Holding Company Up to 13,474,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275117 PROSPECTUS SUPPLEMENT NO. 19 (to Prospectus dated March 29, 2024) Scilex Holding Company Up to 13,474,683 Shares of Common Stock This prospectus supplement supplements the prospectus dated March 29, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No |
|
| December 13, 2024 |
Exhibit 4.3 COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANY Warrant Shares: Issue Date: December 13, 2024 Initial Exercise Date: June 13, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| December 13, 2024 |
Exhibit 4.4 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This Amendment No. 1 (this “Amendment”) to that certain Common Stock Purchase Warrant, issued on March 5, 2024 (the “Warrant”), is made and entered into as of December 11, 2024 by and between Scilex Holding Company (the “Company”) and Armistice Capital Master Fund Ltd. (the “Holder”). Capitalized terms used but not otherwise defined here |
|
| December 10, 2024 |
EX-10.3 Exhibit 10.3 December 9, 2024 SCLX Stock Acquisition JV 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Xiao Xu And Scilex Holding Company 960 San Antonio Rd. Palo Alto, CA 94303 Attn: Stephen Ma VIA EMAIL RE: Consent under Securities Purchase Agreement and Tranche B Senior Secured Convertible Note (this “Consent Letter”) Ladies and Gentlemen: Reference is made to (i) that certain Securities |
